title: Failure of ketamine anesthesia in a patient with lamotrigine overdose.
abstract: Introduction. It is important to know which clinical situations prevent ketamine from working. Case Report. We present the case of the psychiatric inpatient who was admitted to our emergency department after ingesting a toxic dose of lamotrigine, unknown at that time. On admission, she was clearly in distress, displaying extreme agitation and violent ataxic movements. We opted to achieve sedation using intravenous ketamine boluses. Unexpectedly, after being injected with a total of 250 mg ketamine, our patient displayed no signs of dissociative anaesthesia. Discussion. There was no apparent reason for why ketamine failed, but an interaction between lamotrigine and ketamine was suspected. A literature search was performed. Very few articles describe interactions between lamotrigine and ketamine. Experimental studies, however, demonstrate how lamotrigine attenuates the neuropsychiatric effects of ketamine. Ketamine is classically described as an NMDA antagonist. Ketamine's dissociative effects, however, are thought to be mediated by increased glutamate release via a pathway not dependent on NMDA receptors. Lamotrigine, on the other hand, is known to reduce cortical glutamate release. Conclusion. Lamotrigine reduces the glutamate release needed to mediate ketamine's dissociative anaesthesia. This is important knowledge for anaesthesiologists in the emergency room where ketamine is often administered to unstable patients.
authors.affiliation: Department of Anesthesiology, Nordland Hospital, 8095 Bodø, Norway.
authors.forename: Daniel
authors.initials: D
authors.lastname: Kornhall
authors.affiliation: Department of Anesthesiology, Nordland Hospital, 8095 Bodø, Norway ; Institute of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway ; University of Nordland, 8049 Bodø, Norway.
authors.forename: Erik Waage
authors.identifier: 0000-0002-8358-3226
authors.initials: EW
authors.lastname: Nielsen
references.citation: Arch Gen Psychiatry. 2008 Feb;65(2):154-64
references.pmid: 18250253
references.citation: Drugs. 1995 Oct;50(4):691-713
references.pmid: 8536554
references.citation: Anesthesiology. 1997 Jun;86(6):1326-33
references.pmid: 9197302
references.citation: Arch Gen Psychiatry. 2000 Mar;57(3):270-6
references.pmid: 10711913
references.citation: Br J Anaesth. 1992 Sep;69(3):292-7
references.pmid: 1327042
references.citation: J Pharmacol Exp Ther. 2013 Apr;345(1):151-60
references.pmid: 23370794
references.citation: Emerg Med J. 2008 Aug;25(8):498-501
references.pmid: 18660398
references.citation: Br J Anaesth. 1996 Oct;77(4):441-4
references.pmid: 8942324
references.citation: Anesth Prog. 1992;39(3):61-8
references.pmid: 1308374
references.citation: J Neurosci. 1997 Apr 15;17(8):2921-7
references.pmid: 9092613
references.citation: Pharmacol Toxicol. 1995 Dec;77(6):355-9
references.pmid: 8835358
references.citation: Science. 1998 Aug 28;281(5381):1349-52
references.pmid: 9721099
references.citation: Ann Pharmacother. 2004 Nov;38(11):1811-5
references.pmid: 15353576
references.citation: CNS Drugs. 2004;18(1):63-7
references.pmid: 14731061